GP73 represses host innate immune response to promote virus replication by facilitating MAVS and TRAF6 degradation
View abstract on PubMed
Summary
This summary is machine-generated.Golgi protein 73 (GP73) facilitates Hepatitis C virus (HCV) infection by suppressing host innate immunity. GP73 degrades key immune signaling proteins, promoting viral replication and suggesting GP73 as an antiviral target.
Area Of Science
- Virology
- Immunology
- Hepatology
Background
- Hepatitis C virus (HCV) causes chronic liver disease and hepatocellular carcinoma (HCC).
- Golgi protein 73 (GP73) is a biomarker for liver disease but its role in HCV infection is unclear.
- Understanding GP73's function is crucial for developing new antiviral strategies.
Purpose Of The Study
- To elucidate the mechanism by which GP73 regulates host innate immunity during HCV infection.
- To investigate the interaction between GP73 and key host antiviral signaling pathways.
- To determine if GP73 can be a therapeutic target for HCV-associated diseases.
Main Methods
- Analysis of GP73 expression in HCV-infected patients and cell models.
- Investigating the role of GP73 in the mitochondrial antiviral signaling protein (MAVS) and TNF receptor-associated factor 6 (TRAF6) pathway.
- Utilizing knockdown and mutant cell models to assess the impact of GP73 on HCV replication.
- Assessing the effects of GP73 on interferon-beta (IFN-β) and other immune response elements.
Main Results
- GP73 expression is upregulated during HCV infection and correlates with IFN-β production.
- GP73 interacts with MAVS and TRAF6, promoting their degradation via the proteasome pathway.
- GP73 inhibits IFN-β, IFN-λ1, IL-6, and ISG56 expression, thereby suppressing innate immunity.
- Knockdown of GP73 reduces HCV infection and replication, which is rescued by a resistant GP73 mutant.
Conclusions
- GP73 acts as a negative regulator of host innate immunity, facilitating HCV infection.
- GP73 promotes HCV pathogenesis by degrading MAVS/TRAF6 and suppressing antiviral responses.
- GP73 represents a novel therapeutic target for preventing and treating HCV infection and related liver diseases.